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Abstract Allosteric modulators for adenosine receptors
may have potential therapeutic advantage over orthosteric
ligands. Allosteric enhancers at the adenosine A1 receptor
have been linked to antiarrhythmic and antilipolytic
activity. They may also have therapeutic potential as
analgesics and neuroprotective agents. A3 allosteric
enhancers are postulated to be useful against ischemic
conditions or as antitumor agents. In this review, we
address recent developments regarding the medicinal
chemistry of such compounds. Most efforts have been and
are directed toward adenosine A1 and A3 receptors, whereas
limited or no information is available for A2A and A2B
receptors. We also discuss some findings, mostly receptor
mutation studies, regarding localization of the allosteric
binding sites on the receptors.
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Abbreviations
AR adenosine receptor
cAMP cyclic adenosine monophosphate
cDNA complementary deoxyribonucleic acid
CGS21680 2-[p-(2-carboxyethyl)phenyl-ethylamino]-
5’-N-ethylcarboxamidoadenosine
CGS15943 5-amino-9-chloro-2-(2-furyl)-1,2,4-tria-
zolo[1,5-c]quinazoline
CHO Chinese hamster ovary
Cl-IB-MECA 2-chloro-N
6-(3-iodobenzyl)-5’-N-methyl-
carboxamidoadenosine
CP cyclopentyl
DMA 5-(N,N-dimethyl)amiloride
DMF dimethylformamide
DMSO dimethylsulfoxide
DPCPX 8-cyclopentyl-1,3-dipropylxanthine
DU124183 2-cyclopentyl-4-phenylamino-1H-imidazo
[4,5-c]quinoline
GPCR G protein-coupled receptor
GTPγS guanosine 5’-[γ-thio]triphosphate
h human
HMA 5-(N,N-hexamethylene)amiloride
HPLC-MS high-performance liquid chromatography
mass spectrometry
I-ABA N
6–4-amino-3-iodo-benzyladenosine
I-AB-MECA N
6-(4-amino-3-iodobenzyl)-5’-N-methyl-
carbamoyladenosine
LUF6000 N-(3,4-dichlorophenyl)-2-cyclohexyl-1H-
imidazo[4,5-c]quinolin-4-amine
MRS1754 8-(4-[{(4-cyanophenyl)carbamoylmethyl}
oxy]phenyl)-1,3-di(n-propyl)xanthine
NECA 5’-N-ethylcarboxamidoadenosine
PD 71,605 (2-amino-4,5,6,7-tetrahydro-benzo[b]
thiophen-3-yl)-(2-chloro-phenyl)-methanone
PD 117,975 (2-amino-6-benzyl-4,5,6,7-tetrahydro-
thieno[2,3-c]pyridin-3-yl)(4-chloro-phenyl)
methanone
PD 81,723 2-amino-4,5-dimethyl-3-thienyl-[3-
(trifluoromethyl)phenyl]methanone
R-PIA N
6-[(R)-phenylisopropyl]adenosine
SAR structure-activity relationships
SCH-202676 (N-(2,3-diphenyl-[1,2,4]thiadiazole-5(2H)-
ylidene)methanamine)
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VUF5455 4-methoxy-N-[7-methyl-3-(2-pyridinyl)-1-
isoquinolinyl]benzamide
VUF8502 4-methyl-N-[3-(2-pyridinyl)-1-isoquino-
linyl]benzamide
VUF8504 4-methoxy-N-[3-(2-pyridinyl)-1-isoquino-
linyl]benzamide
VUF8507 N-[3-(2-pyridinyl)-1-isoquinolinyl]benzamide
ZM241385 4-{2-[7-amino-2-(2-furyl)-1,2,4-triazolo
[1,5-a]1,3,5]triazin-5-yl-amino]ethyl}phenol
Introduction
The superfamily of human G protein-coupled receptors
(GPCRs) consists of three major classes: A, B, and C. Class
A, also termed rhodopsin-like after the prototypic visual
pigment, constitutes the largest group of GPCRs. Adenosine
receptors belong to this class. Four subtypes of adenosine
receptors have been cloned and pharmacologically charac-
terized: A1,A 2A,A 2B,a n dA 3. Among the human
adenosine receptors, the most similar are A1 and A3 (49%
sequence similarity) and A2A and A2B (59% similarity).
Activation of A1 and A3 receptors induces the inhibition of
the enzyme adenylate cyclase mediated by an inhibitory G
protein (Gi). Activation of A2A and A2B receptors leads to a
Gs-mediated stimulation of this enzyme [1].
Many representatives of class A receptors, among them
adenosine receptors, have been shown to be allosterically
regulated. Allosteric refers to binding sites that are different
from the orthosteric primary ligand-binding site to which
ligands such as endogenous adenosine and synthetic
derivatives thereof bind. The binding of modulators is
supposed to result in conformational changes of the
receptor that affect binding of the orthosteric ligand with
consequences for receptor activity (see Fig. 1).
Strictly speaking, the allosteric modulator in this
scenario has no activity by itself and needs the orthosteric
ligand (often the endogenous hormone or neurotransmitter)
in order to become activated. The nature of allosteric
modulation is therefore very much dependent on this
orthosteric ligand. As a consequence, the overall pharma-
cology invoked by the allosteric modulator resembles
physiology more closely than is possible with most of
today’s drugs, i.e., synthetic orthosteric ligands (see Fig. 2
for the effect of an allosteric enhancer).
The concept of allosteric modulation of established drug
targets such as GPCRs has fueled an intensive quest for
new classes of lead compounds different from classic
agonists and antagonists. This has been the subject of
several recent reviews [2–5]. As adenosine receptors were
among the first GPCRs found to be allosterically regulated,
these receptors have often been reviewed also [6–8]. The
aim of this review is to summarize the latest developments
in this fascinating field for all four subtypes of adenosine
receptors, with a twofold emphasis. First, chemical classes
of allosteric ligands, their receptor preference, and structure-
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Fig. 1 Binding of an allosteric ligand (1) modulates the binding of
hormone or neurotransmitter (2)
a Action of endogenous agonist 
b Action of endogenous agonist in the presence
of an allosteric enhancer 
c Action of synthetic agonist 
effect 
effect 
effect 
Time 
Time 
Time 
Fig. 2 Allosteric modulators may either increase or decrease the
effect of an agonist or an antagonist. An allosteric enhancer can be a
more physiologic alternative to synthetic agonists (b, c). An allosteric
enhancer can only act in the presence of an (endogenous) agonist. It
mimics the duration and intensity of action of a hormone or
neurotransmitter (a) much better than a synthetic agonist does (c).
This combined action of two compounds (i.e., agonist and enhancer)
might also induce selectivity of drug action
52 Purinergic Signalling (2009) 5:51–61activity relationships (SAR) are discussed. Second, attention
is given to the putative binding site of the modulators.
A1 adenosine receptors
Baraldi et al. recently published an extensive review of
allosteric modulators of A1 receptors [8]. Here, we briefly
provide an overview of historical as well as new allosteric
modulators for A1 adenosine receptors. Bruns and coworkers
introduced the first allosteric modulators of the A1 receptor in
1990 [9, 10]. Three compounds, (2-amino-4,5,6,7-tetrahydro-
benzo[b]thiophen-3-yl)-(2-chloro-phenyl)-methanone (PD
71,605); 2-amino-4,5-dimethyl-3-thienyl-[3-(trifluoromethyl)
phenyl]methanone (PD 81,723); and (2-amino-6-benzyl-
4,5,6,7-tetrahydrothieno[2,3-c]pyridin-3-yl)(4-chloro-phenyl)
methanone (PD 117,975) were studied in detail (see Fig. 3).
These chemical structures were part of the Parke-Davis
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Fig. 3 2-Amino-3-substituted
thiophene derivatives, allosteric
modulators for A1 adenosine
receptors
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as intermediates in the synthesis of benzodiazepine-like
compounds [11].
Their allosteric-enhancing nature was identified by
accident while screening the library in a radioligand-
binding assay at the rat A1 adenosine receptor. The three
compounds increased rather than decreased (the original
aim of the screening campaign) the binding of the agonist
radioligand [
3H]N
6-cyclohexyladenosine to A1 receptors in
rat-brain membranes. The enhancers appeared to slow the
dissociation of the agonist [
3H]N
6-cyclohexyladenosine
from the A1 receptor, indicating an allosteric mechanism
of action. These compounds were also competitive antago-
nists at the same receptor. Therefore, the concentration range
withinwhichthesecompoundsenhancetheeffects ofagonists
is limited. Among the compounds tested by Bruns et al., PD
81,723 stood out as one of the more potent compounds with
the best ratio of enhancing to antagonistic action. PD 81,723
hasbeenthoroughlyandindependentlystudiedovertheyears,
and it became the reference allosteric modulator of A1
receptors. It has been extensively modified structurally
[9, 10].
Van der Klein and colleagues synthesized a new series of
2-amino-3-benzoylthiophenes with PD 81,723 as a tem-
plate. Among these compounds, 1–3 (Fig. 3) proved to be
more potent enhancers than PD 81,723, with comparable
antagonistic activity. The biological assays were carried out
on membranes of rat-brain cortex, and the enhancing
activity was measured at 10 μM of test compound. For
compound 1, enhancement was 122%; for compound 2,
123%; and for compound 3, 151% compared with that of
PD 81,723 (100%).
It was concluded that in this class of 2-amino-3-
benzoylthiophene derivatives, lipophilic benzoyl (3-CF3,
3,4-Cl, or 4-t-butyl) substitution and thiophene 4-alkyl
substitution favored allosteric enhancing activity. Thiophene
5-bulky substitution favored antagonistic properties, which
rendered the separation of these two activities in these
structures possible [12, 13].
Baraldi et al. also developed a series of PD 81,723
analogues. For their pharmacological evaluation, cyclic
adenosine monophosphate (cAMP) determinations were
carried out in Chinese hamster ovary (CHO) cells expressing
human A1 receptors (CHO:hA1) vs. radioligand dissociation
experiments on rat-brain membranes. In their studies,
compounds 2, 4, and 5 (Fig. 3)p r o v e dt ob en e a r l ya s
efficacious (effect on Emax) as and more potent (effect on
EC50) than PD 81,723 and caused a significant reduction of
the cAMP content of CHO:hA1 cells at a concentration of
0.1 μM[ 14]. In a later and more extensive study, the same
authors investigated a large number of 2-amino-3-
naphthoylthiophenes [15]. Among these compounds, 6 was
the most active, increasing agonist binding to CHO:hA1,
human-brain, and rat-cortex membranes by 149%, 43%, and
27% (51%, 15%, and 22% for PD 81,723). In the series of
4,5,6,7-tetrahydrothieno[2,3-c]pyridine derivatives, the only
compound that showed significant allosteric enhancer activity
atanyconcentrationwascompound7. A series of 2-amino-3-
heteroarylthiophenes have also been synthesized. The same
functional cAMP assay also revealed that compounds 8–11
are allosteric enhancers at the human A1 receptor. Replace-
ment of the phenyl ring at the 3 position of the thiophene
ring with a 2-or 3-thienyl moiety maintained the enhancing
activity of PD 81,723 [16]. Thieno[2,3-c]pyridine derivatives
were accessed by the Baraldi group by means of microwave-
assisted synthesis. Among the prepared compounds, 12
showed activity comparable with that of PD 81,723
(Fig. 3)[ 17].
Tranberg et al. also performed a systematic survey of the
PD 81,723 lead structure. The 3-OMe derivative 13 had
high enhancing activity and relatively low antagonistic
potency: 99% and 13%, respectively, at 100 μM[ 18]. The
same research group showed that chemical structures more
different from the prototypic PD 81,723 were allosteric
enhancers also [19]. The allosteric enhancing activity score
of PD 81,723 was 19% and served as a standard for
comparison. For compound 14, it was 48%; and for the 3-
(1-naphthoyl substituted compound 15, it was 52%. Com-
pounds 16 and 17 seemed to be more potent, with scores of
91% and 80%, respectively (Fig. 3). In this study
assessment of allosteric enhancing activity was done in a
somewhat different way and consisted of three phases: (1)
binding to equilibrium of the agonist N
6–4-amino-3-iodo-
benzyladenosine (
125I-ABA) to the A1 adenosine receptor–
G protein ternary complex, (2) stabilization of that complex
by the allosteric enhancer, and (3) dissociation of the
complex by adding a combination of an A1 receptor
antagonist and guanosine 5’-[γ-thio]triphosphate (GTPγS),
to accelerate agonist radioligand dissociation. A score of
100% means no dissociation and a score of zero complete
dissociation. Similarly, Nikolakopoulos et al. studied 2-
aminothiophene-3-carboxylates and carboxamides as adeno-
sine A1 receptor allosteric enhancers. Compound 18 was
notably more potent and efficacious than PD 81,723 (Fig. 3)
[20]. Interestingly, 2-aminoselenophene-3-carboxylates also
proved to be allosteric enhancers of A1 receptors [21].
In 2006, the first radiolabeled adenosine A1 allo-
steric enhancer, the tritiated form of compound 2, was
prepared (Fig. 3). The biological investigation of this
compound, 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-
yl)-(4-chlorophenyl)-methanone ([
3H]T-62), suggested the
presence of an allosteric binding site on the adenosine A1
receptor distinct from the orthosteric binding site for
agonists and antagonists [22].
Another chemical class of allosteric enhancers of agonist
binding at cloned hA1 adenosine receptors are the 2-
54 Purinergic Signalling (2009) 5:51–61aminothiazoles. The most potent and efficacious enhancer
of the series reported is compound 19 (Fig. 4). The potency
of this 2-aminothiazole derivative was reported to be 127
times that of PD 81,723 (EC50 values 0.3 μM and 38 μM,
respectively). The intrinsic activity of compound 19 was
about twice that of PD 81,723. The enhancing effect at A2A
and A3 receptors by this compound was found to be weak
[23].
We also prepared a number of 2-aminothiazoles and their
amide derivatives. The 2-aminothiazoles (the free bases)
were tested as allosteric enhancers of agonist binding to
human A1 receptors. In a variety of experimental setups, the
compounds showed no such effect, in contrast to the above
findings of Chordia et al. [23]. Some of the amides emerged
as moderately active antagonists on human A1 and/or A2A
receptors, with lower or negligible potency at A3 receptors
[24].
Chordia et al. next investigated these contrasting find-
ings in more detail and concluded that the free bases of this
type of compound in fresh solutions are only weakly active
as allosteric enhancers. However, the allosteric enhancing
activity in solutions of these compounds in dimethylforma-
mide (DMF), dimethylsulfoxide (DMSO), or acetonitrile
increased after 4 h and finally led to a constant activity
equivalent to that of the hydriodide salts after 12 h [25].
Fawzi et al. reported SCH-202676 (N-(2,3-diphenyl-
[1,2,4]thiadiazole-5(2H)-ylidene)methanamine) to act as a
more promiscuous agent (Fig. 4). It appeared to modulate
the activity of many GPCRs, including opioid, muscarinic,
adrenergic, and dopaminergic receptors [26]. We studied its
activity on adenosine receptors. We also synthesized a
number of 2,3,5-substituted [1,2,4]thiadiazole analogues of
SCH-202676 and tested these as potential allosteric
modulators of adenosine receptors. SCH-202676 displayed
a mixed behavior on adenosine receptors. It displaced
agonist binding to A1 receptors in a reversible manner and
both agonist and antagonist binding to A2A receptors. The
displacement curves were very steep, dissimilar to normal
competitive displacement curves. On A1 receptors, com-
pound 20 was shown to be an allosteric enhancer of
antagonist 8-cyclopentyl-1,3-dipropylxanthine ([
3H]
DPCPX) binding (Fig. 4)[ 27].
In our next work, we investigated a new series of 2,3,5-
substituted [1,2,4]thiadiazoles. Results of receptor-ligand-
bindingexperimentsandstabilitystudiesbyhigh-performance
liquid chromatography (HPLC) and HPLC mass spec-
trometry (MS) showed that the compounds are highly
reactive sulfhydryl-modifying agents rather than allosteric
inhibitors. They appear to be reduced into their thiourea
precursors by thiol groups of, e.g., cysteine residues in
proteins. This general feature most probably explains their
overall lack of selectivity [28].
Amiloride (a diuretic) also acts as a promiscuous agent,
which had been reported before to interact with many
GPCRs such as α2-adrenergic receptors [29]. Results by
Garritsen et al. suggest that amiloride interacts with the A1
receptor at a site distinct from the ligand-binding site.
Furthermore, amiloride appeared to be an A1 receptor
antagonist with binding characteristics that differ from the
classic A1 receptor antagonists such as DPCPX [30–31].
Allosteric modulation of A1 receptors has been demon-
strated not only in vitro but also in vivo in various species,
including humans. Local administration of PD 81,723 in
rats caused a concentration-dependent increase of extracel-
lular acetylcholine levels of approximately 40%. However,
the antagonistic actions of the allosteric enhancer PD
81,723 on the adenosine A1 receptor canceled the allosteric
actions [32]. Treating dogs with PD 81,723 reduced the
time required for ischemia to produce preconditioning [33].
Compound 2 (T-62) has been in preclinical development for
the treatment of chronic pain [34, 35] and is now in phase II
clinical trials (King Pharmaceuticals).
A2A adenosine receptors
Although an allosteric enhancer for the A2A receptors has not
yet been developed, amiloride and analogues were demon-
strated to be allosteric inhibitors also for the A2A receptor.
Among the derivatives tested, 5-(N,N-hexamethylene)
amiloride (HMA) proved to be the most potent allosteric
inhibitor (Fig. 5). Amiloride analogues increased the
dissociation rate of the antagonist 4-{2-[7-amino-2-
(2-furyl)-1,2,4-triazolo[1,5-a]1,3,5]triazin-5-yl-amino]ethyl}
phenol ([
3H]ZM241385) from the A2A receptor. However
they did not show any effect on the dissociation rate of the
agonist 2-[p-(2-carboxyethyl)phenyl-ethylamino]-5’-N-ethyl-
carboxamidoadenosine ([
3H]CGS21680) [36]. In contrast to
S
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Fig. 4 2-Aminothiazoles and
[1,2,4]thiadiazole analogues,
questionable allosteric modula-
tors for A1 adenosine receptors
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sodium ions decreased the dissociation rate of the antagonist
[
3H]ZM241385 from the A2A receptor in a concentration-
dependent manner.
Gao and collegues later showed that amiloride analogues
are also allosteric inhibitors of antagonist binding at A1 and
A3 receptor subtypes [37]. Amiloride and 5-(N,N-dimethyl)
amiloride (DMA) were more potent at A1 receptors than at
A3 receptors, whereas HMA was more potent at A3
receptors (Fig. 5).
A2B adenosine receptors
Allosteric modulators for A2B receptors have not yet been
described. Research on the A2B receptor subtype has been
hampered by the lack of suitable, commercially available
radioligands. However, with the advent of the radiolabeled
antagonist 8-(4-[{(4-cyanophenyl)carbamoylmethyl}oxy]
phenyl)-1,3-di(n-propyl)xanthine ([
3H]MRS1754) and other
radioligands, such studies are now feasible. Still, a radio-
labeled agonist is not yet available, which is hindering the
identification of allosteric enhancers of agonist binding.
A3 adenosine receptors
Gao et al. reported the first selective allosteric enhancers of
agonist binding at human A3 receptors [38]. The effects of the
reference A3 receptor agonist 2-chloro-N
6-(3-iodobenzyl)-5’-
N-methylcarboxamidoadenosine (Cl-IB-MECA) on forskolin-
induced cAMP formation were significantly enhanced by
several 3-(2-pyridinyl)isoquinoline derivatives. Most com-
pounds, however, also displayed orthosteric binding affinity
to the human A3 receptor. Their results indicated that 4-
methoxy-N-[7-methyl-3-(2-pyridinyl)-1-isoquinolinyl]benza-
mide (VUF5455) (see Fig. 6) is selective for the agonistic
state of the A3 receptor. In competitive binding studies on
cloned human A3 receptors VUF5455 is rather weak as an
orthosteric ligand (Ki=1680 nM). Replacement of the 7-
methyl group of VUF5455 by H [4-methoxy-N-[3-(2-
pyridinyl)-1-isoquinolinyl]benzamide (VUF8504)] had no
influence on the allosteric activity but increased the A3
receptor affinity nearly 100-fold (Ki=17.3 nM). Exchanging
the 4’-methoxy group of VUF8504 by methyl [4-methyl-N-
[3-(2-pyridinyl)-1-isoquinolinyl]benzamide (VUF8502)] or H
[N-[3-(2-pyridinyl)-1-isoquinolinyl]benzamide (VUF8507)]
lowered the A3 receptor affinity (Ki values of 96 nM and
204 nM, respectively) without affecting the allosteric activity.
The corresponding imino instead of carboxamido analogues
displayed moderate A3 affinity (Ki values 300–700 nM) but
were devoid of allosteric properties. Thus, although VUF5455
is not devoid of A3 receptor antagonistic activity, the
compound might be used as a lead for the design of pure
allosteric enhancers of A3 receptors.
Van Galen et al. identified 1H-imidazo-[4,5-c]quinolines
as nonxanthine adenosine receptor antagonists [39]. Later,
these types of compounds were shown to represent a
second series of allosteric modulators for the A3 receptor.
Among these compounds, 2-cyclopentyl-4-phenylamino-
1H-imidazo[4,5-c]quinoline (DU124183) (see Fig. 6) se-
lectively enhanced agonist binding and function at A3
receptors, similar to VUF5455. However, in contrast to
VUF5455, DU124183 also increased the maximum efficacy
of A3 receptor agonists in the cAMP assay with cloned
human A3 receptors. For DU124183, there was a marked
leftward shift of the concentration-response curve of the A3
receptor agonists in the presence of an orthosteric antago-
nist and a potentiation of the maximum agonist efficacy by
approximately 30%. In competitive binding studies,
DU124183 also displayed some orthosteric activity, as it
bound with moderate affinity (Ki=820 nM) to human A3
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56 Purinergic Signalling (2009) 5:51–61Table 1 Potency of 1H-imidazo[4,5-c]quinoline-4-amine derivatives in binding assays at human A1,A 2A,A 2B and A3 adenosine receptors
expressed in CHO cells and allosteric effects at the human A3 adenosine receptors
a
N
N
N
N
R'
R
2
4
24 PhCH2  CP  28%  77% -3.4% 86%  145±10 147±8 
25 Ph(CH2)2  CP  52%  91% -11.6% 84%  154±7 137 ±4 
26 3,4-Cl2-Ph Cheptyl  -4%  -2%  -7.3%  68%  130±2 115 ±7 
27 3,4-Cl2-Ph  O -4% 70%  9.0%  78%  98±3 95 ±4 
 3,4-Cl2-Ph 
LUF6000 
Chexyl -2%  -1% -5.6% 45%  173±5 145±7
28 3,4-Cl2-Ph Cbutyl  -5%  0.4%  -5.5%  52%  116±3 126 ±3 
29 3,4-Cl2-Ph 1.8% -0.8%  10.2% 39%  91±7 92 ±4 
No.  R R’ 
Ki 
(hA1AR) 
nM
 a or 
% displ. 
at 
10 µM 
Ki 
(hA2AAR) 
nM
 a or 
% displ. 
at 10 µM 
hA2BAR
% 
inhib. 
at  
10 µM
b 
Ki 
(hA3AR) 
nM
 a 
or % 
displ. at 
10 µM 
hA3AR ag. 
Diss.  
(%)
 c 
at 10 µM 
Relative 
efficacy 
(%) at 
hA3AR
 d 
at 10 µM 
 Ph 
(DU124183) 
CP 
 
3420 ± 
230 
 
3150 ± 
210 
 
-6.8% 
 
786 ± 67 
(90%) 
 
174±5 
 
138±8 
21 4-Cl-Ph  CP 
>10,000 
(22%) 
>10,000 
 (17%)  -10.2% 
1610 ± 
550 
(82%) 
159±5 136 ±3 
22 
 
CP 21%  8% -10.7% 69%  108±4 111 ±5 
23 
N
H
N
 
CP 56%  68%  5.0%   67%  109±3 96 ±2 
H
30 3,4-Cl2-Ph  n-pentyl 43.9%  -1%  -9.3%  84%  116±5 102±5 
aAll experiments were performed using adherent CHO cells stably transfected with cDNA encoding the human adenosine receptors. Binding at
human A1,A 2A and A3 adenosine receptors in this study was carried out as described in Experimental Procedures using [
3H]R-PIA, [
3H]CGS
20080 or [
125I]I-AB-MECA as a radioligand. Values from the present study are expressed as mean ± s.e.m., n=3–5. Percentage inhibition at A1,
A2A,o rA 3 receptors is expressed as the mean value from 2–4 separate experiments with similar results performed in duplicate.
bA2B adenosine receptor: effect of compounds at 10 μM on NECA (150 nM)-induced cAMP accumulation from one experiment performed in
triplicate, CGS15943 (10 μM) = 100%.
cdissociation: % decrease of [
125I]I-AB-MECA dissociation at 30 min (control=100%)
dincrease of efficacy: compared to maximal effect by 2-Cl-IB-MECA alone (control=100%)
Purinergic Signalling (2009) 5:51–61 57receptors. Some members of this series also had a compet-
itive interaction with the A1 adenosine receptor [39, 40].
The aim of a subsequent study was the optimization of
DU124183. Structural modifications were made at the 4-
amino and 2 positions of the molecule, partly using the
Topliss scheme [41]. The compounds were tested in
binding and functional assays (Table 1). SARs for the
allosteric enhancing effects showed that at the 4-amino
position, a phenyl ring or substituted monocyclic phenyl
ring (compounds DU124183, 21) was more enhancing than
bicyclic aryl rings (compounds 22, 25). A phenyl group
(DU124183) was also better in enhancing than the
corresponding benzyl and phenylethyl groups (24, 25). As
noted previously, substitution at the 2-position was also
necessary for allosteric enhancement (compound 29). At this
position, medium-sized cycloalkyl substituents (cyclopentyl
and cyclohexyl) were most favorable for enhancement.
Analogues bearing smaller or larger rings (compounds 28,
26) or an acyclic alkyl group (compound 30)w e r e
considerably less enhancing, and similarly an aromatic five-
membered ring (compound 27) was not conductive to
enhancement. Two compounds, 2-cyclopentyl-4-benzyla-
mino (24) and 2-cyclohexyl-4-(3,4-dichlorophenyl)amino
(LUF6000, see Fig. 6) analogues potentiated the maximum
efficacy of the agonist Cl-IB-MECA by 45–50% (Table 1).
Moreover, LUF6000 enhanced agonist efficacy in a func-
tional assay and decreased the agonist dissociation rate
without influencing agonist potency. Most allosteric
enhancers in this study only modestly inhibited orthosteric
ligand binding, if at all. Apparently, structural requirements
for allosteric enhancement at the A3 receptor are distinct
from those for the inhibition of equilibrium radioligand
binding. This suggests even greater selectivity is feasible in a
future lead optimization program. Allosteric enhancers of A3
receptor activation are predicted to be useful against a
number of disorders, including ischemic conditions and
cancer. LUF6000 showed no effect on the basal receptor
activity yet showed a significant enhancement of agonist
action. This result suggests that such enhancers could be
safer drugs and would be particularly effective to enhance
agonist efficacy under pathophysiological conditions such as
brain and heart ischemia, where adenosine and inosine
concentrations are greatly increased [42; Gao et al.,
manuscript submitted 2008].
Mutagenesis studies, binding sites for allosteric
modulators
The aim of several publications was to determine where the
binding sites are for allosteric modulators on adenosine
receptors. Theoretically, it might be possible that PD 81,723
binds to another protein, such as a G-protein subunit, and that
this complex allosterically regulates the A1 receptor. Howev-
er, Bhattacharya et al. suggested that PD 81,723 binds to the
A1 receptor itself and that it stabilizes the high-affinity con-
formational state of the A1 receptor–G-protein complex [43].
Site-directed mutagenesis is a useful technique for eluci-
dating ligand–receptor interactions by testing the role of
several amino acids within the receptor. Mutant A1 receptors
have been studied, where glycine at position 14 had been
changed into threonine (G14T). The G14T mutant renders
the receptor constitutively active with (very) high agonist
affinity, upon which PD 81,723 loses its enhancing activity.
It appears that the G14T receptor is “locked” in an active
state and as such does not reveal the site of PD 81,723
binding [44]. Studies on wild-type and mutant (T277A) A1
receptors gave analogous results. Mutation of a threonine
residue to alanine at position 277 in the human A1 receptor
decreased agonist binding to the receptor but also abolished
the effects of PD 81,723 [45]. Again, it would be premature
to conclude that T277 is part of the PD 81,723 binding site.
Fig. 7 The location of amino
acid residues involved in
allosteric modulation of A1,
A2A, and A3 receptors as dis-
played in a receptor homology
model of the adenosine receptor
(side and top view) based on the
structure of the β2-adrenergic
receptor cocrystallized with its
ligand carazolol (PDB coordi-
nates: 2rh1). C-α atoms at these
locations are shown as spheres.
The position of D55 in the A1
receptor is equivalent to D58 in
the A3 receptor
58 Purinergic Signalling (2009) 5:51–61Barbhaiya et al. mutated a largely conserved aspartic
acid residue in TM2 of the A1 receptor to alanine (D55A).
This residue was found to be responsible for allosteric
regulation of ligand-A1 receptor binding by sodium ions
[46]. Gao and colleagues performed mutagenesis experi-
ments on the A2A receptor, where a glutamic acid residue in
TM1 and a histidine residue in TM7 were mutated to
glutamine (E13Q) and tyrosine (H278Y), respectively.
Results suggest that the two closely linked residues Glu13
and His278 in the A2A receptor are the most important for
agonist recognition and partly responsible for the allosteric
regulation by sodium ions [36, 47]. Furthermore Gao et al.
identified residuesinvolved inthe allostericmodulation ofthe
human A3 receptor. A number of residues in the transmem-
brane helical domains were shown to be critically involved
in the recognition of the allosteric modulators. The F182A
(TM5) and N274A (TM7) mutations abolished the allosteric
effects of the two modulators DU124183 and VUF5455 but
had hardly any effect on agonist binding, as was the case for
N30A (TM1) and D58N (TM2). The D107N (TM3) mutation
eliminatedtheeffectsofDU124183butnotofVUF5455[48].
To summarize, site-directed mutagenesis studies may
shed light on amino acids involved in allosteric ligand-
receptor interactions. Experiments to that end have been
carried out on A1,A 2A, and A3 receptors, whereas A2B
receptors have not yet been studied. For A1 receptors,
Asp55 in TM2 is probably responsible for allosteric
regulation of binding by sodium ions and amilorides,
whereas upon G14T (TM1) and T277A (TM7) mutagenesis,
PD 81,723 loses its enhancing activity with respect to
carboxypeptidase A (CPA). For A2A receptors, Glu13 in
TM1 and His278 in TM7 have been shown to be linked to
allosteric regulation by sodium ions. For A3 receptors,
F182A (TM5) and N274A (TM7) mutations abolished the
allosteric effects of the two modulators DU124183 and
VUF5455. The D107N (TM3) mutation eliminated the
effects of DU124183 but not of VUF5455. It is fair to
assume that the residues studied so far only yield a
fragmented view of the amino acids involved in the
allosteric regulation of adenosine receptors. The location
of the residues discussed here is shown in a receptor
homology model of the adenosine receptor based on the
recently reported crystal structure of the β2-adrenergic
receptor [49] (Fig. 7).
Conclusions
Allosteric modulation is a new way of intervening with
receptor function. Because of the ability of allosteric
modulators to modulate receptor conformations in the
presence of orthosteric ligand, allosteric modulators can
“fine tune” classical pharmacological responses. Although an
allosteric modulator may not possess efficacy by itself, it can
provide a powerful therapeutic advantage over orthosteric
ligands, namely, the ability to selectively influence tissue
responses only when the endogenous agonist is present.
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